Miller Anestesia

202 / 2894

31. Kew MC: Hepatic tumors and cysts. In Feldman M,
Friedman LS, Sleisenger MH (eds): Sleisenger &
Fordtran’s Gastrointestinal and Liver Disease:
Pathophysiology/Diagnosis/Management, 7th ed.
St Louis, WB Saunders, 2002, p 1577.
32. Seeff LB: Diagnosis, therapy, and prognosis of viral
hepatitis. In Zakim D, Boyer T (eds): Hepatology: A
Textbook of Liver Disease, 3rd ed. Philadelphia,WB
Saunders, 1996, p 1067.
33. Tirone TA, Brunicardi FC: Overview of glucose
regulation. World J Surg 25:461, 2001.
34. Galassetti P,Coker RH,Lacy DB,et al: Prior exercise
increases net hepatic glucose uptake during a
glucose load. Am J Physiol 276:E1022, 1999.
35. Nordlie RC, Foster JD, Lange AJ: Regulation of
glucose production by the liver. Annu Rev Nutr
19:379, 1999.
36. Satake S, Moore MC, Igawa K, et al: Direct and
indirect effects of insulin on glucose uptake and
storage by the liver. Diabetes 51:1663, 2002.
37. Chu CA, Sindelar DK, Igawa K, et al: The direct
effects of catecholamines on hepatic glucose pro-
duction occur via alpha(1)- and beta(2)-receptors
in the dog. Am J Physiol 279:E463, 2000.
38. Gustavson SM, Chu CA, Nishizawa M, et al: Inte-
raction of glucagon and epinephrine in the control
of hepatic glucose production in the conscious dog.
Am J Physiol 284:E695, 2003.
39. Chu CA, Galassetti P, Igawa K, et al: Interaction of
free fatty acids and epinephrine in regulating
hepatic glucose production in conscious dogs. Am
J Physiol 284:E291, 2003.
40. Chu CA, Sherck SM, Igawa K, et al: Effects of free
fatty acids on hepatic glycogenolysis and gluconeo-
genesis in conscious dogs. [erratum appears in Am
J Physiol Endocrinol Metab 2002 Oct;283(4):section
E following table of contents]. Am J Physiol
282:E402, 2002.
41. Cardin S, Walmsley K, Neal DW, et al: Involvement
of the vagus nerves in the regulation of basal
hepatic glucose production in conscious dogs. Am
J Physiol 283:E958, 2002.
42. Rashid S, Shi ZQ, Niwa M, et al: Beta-blockade, but
not normoglycemia or hyperinsulinemia, markedly
diminishes stress-induced hyperglycemia in diabe-
tic dogs. Diabetes 49:253, 2000.
43. Cardin S, Emshwiller M, Jackson PA, et al: Portal
glucose infusion increases hepatic glycogen deposi-
tion in conscious unrestrained rats. J Appl Physiol
87:1470, 1999.
44. Hsieh PS, Moore MC, Neal DW, et al: Importance
of the hepatic arterial glucose level in generation of
the portal signal in conscious dogs. Am J Physiol
279:E284, 2000.
45. Stolz A: Liver physiology and metabolic function.
In Feldman M, Friedman LS, Sleisenger MH
(eds): Sleisenger & Fordtran’s Gastrointestinal
and Liver Disease: Pathophysiology/Diagnosis/
Management, 7th ed. St Louis, WB Saunders,
2002, p 1202.
46. Riou JP,Claus TH,Pilkis SJ: Stimulation of glucagon
of in vivo phosphorylation of rat hepatic pyruvate
kinase. J Biol Chem 253:656, 1978.
47. Sharma RJ, Rodrigues LM, Whitton PD, et al:
Control mechanisms in the acceleration of hepatic
glycogen degradation during hypoxia. Biochim
Biophys Acta 630:414, 1980.
48. Lewis GF: Fatty acid regulation of very low density
lipoprotein production. Curr Opin Lipidol 8:146,
1997.
49. Lewis GF, Vranic M, Harley P, et al: Fatty acids
mediate the acute extrahepatic effects of insulin on
hepatic glucose production in humans. Diabetes
46:1111, 1997.
50. Lewis GF, Vranic M, Giacca A: Role of free fatty
acids and glucagon in the peripheral effect of
insulin on glucose production in humans. Am J
Physiol 275:E177, 1998.
51. Taghibiglou C, Rashid-Kolvear F, Van Iderstine SC,
et al: Hepatic very low density lipoprotein–ApoB
overproduction is associated with attenuated
hepatic insulin signaling and overexpression of
protein-tyrosine phosphatase 1B in a fructose-fed
hamster model of insulin resistance. J Biol Chem
277:793, 2002.
52. Lam TK, Carpentier A, Lewis GF, et al: Mechanisms
of the free fatty acid–induced increase in hepatic
glucose production. Am J Physiol 284:E863, 2003.
53. Chan L, Jackson RL, O’Malley BW, et al: Synthesis
of very low density lipoproteins in the cockerel.
Effects of estrogen. J Clin Invest 58:368, 1976.
54. Miles JM, Haymond MW, Gerich JE: Suppression of
glucose production and stimulation of insulin secre-
tion by physiological concentrations of ketone bodies
in man. J Clin Endocrinol Metab 52:34, 1981.
55. Fitz JG: Cellular mechanisms of bile secretion. In
Zakim D, Boyer T (eds): Hepatology: A Textbook of
Liver Disease, 3rd ed. Philadelphia, WB Saunders,
1996, p 362.
56. Dawson PA: Bile secretion and the enterohepatic
circulation of bile acids. In Feldman M, Friedman
LS, Sleisenger MH (eds): Sleisenger & Fordtran’s
Gastrointestinal and Liver Disease: Pathophysio-
logy/Diagnosis/Management, 7th ed. St Louis, WB
Saunders, 2002, p 1051.
57. Leonis MA, Balistreri WF: Inherited metabolic
disorders of the liver. In Feldman M, Friedman LS,
Sleisenger MH (eds): Sleisenger & Fordtran’s Gas-
trointestinal and Liver Disease: Pathophysiology/
Diagnosis/Management, 7th ed. St Louis,WB Saun-
ders, 2002, p 1240.
58. Vlahcevic ZR, Heuman DM, Hylemon PB: Physio-
logy and pathophysiology of enterohepatic circula-
tion of bile acids. In Zakim D, Boyer T (eds):
Hepatology: A Textbook of Liver Disease, 3rd ed.
Philadelphia, WB Saunders, 1996, p 376.
59. Radnay PA,Duncalf D,NovakovicM,et al:Common
bile duct pressure changes after fentanyl, morphine,
meperidine, butorphanol, and naloxone. Anesth
Analg 63:441, 1984.
60. Fitz JG: Hepatic encephalopathy, hepatopulmonary
syndromes, hepatorenal syndrome, coagulopathy,
and endocrine complications of liver disease. In
Feldman M, Friedman LS, Sleisenger MH (eds):
Sleisenger & Fordtran’s Gastrointestinal and Liver
Disease: Pathophysiology/Diagnosis/Management,
7th ed. St Louis, WB Saunders, 2002, p 1543.
61. Nelsestuen GL, Shah AM, Harvey SB: Vitamin
K–dependent proteins. Vitam Horm 58:355, 2000.
62. Sunnerhagen M, Drakenberg T, Forsen S, et al:
Effect of Ca2+ on the structure of vitamin K–depen-
dent coagulation factors. Haemostasis 26:45, 1996.
63. Berkner KL: The vitamin K–dependent carboxylase.
J Nutr 130:1877, 2000.
64. Dowd P, Ham SW, Naganathan S, et al: The mecha-
nism of action of vitamin K.Annu Rev Nutr 15:419,
1995.
65. Furie BC, Furie B: Structure and mechanism of
action of the vitamin K–dependent gamma-gluta-
myl carboxylase: Recent advances from mutagene-
sis studies. Thromb Haemost 78:595, 1997.
66. Suttie JW: Synthesis of vitamin K–dependent pro-
teins. FASEB J 7:445, 1993.
67. Sugiura I, Furie B, Walsh CT, et al: Propeptide and
glutamate-containing substrates bound to the
vitaminK–dependentcarboxylaseconvertitsvitamin
K epoxidase function from an inactive to an active
state. Proc Natl Acad Sci U S A 94:9069, 1997.
68. Ponka P: Cell biology of heme. Am J Med Sci
318:241, 1999.
69. Ferreira GC, Gong J: 5-Aminolevulinate synthase
and the first step of heme biosynthesis. J Bioenerg
Biomembr 27:151, 1995.
70. Daniell WE, Stockbridge HL, Labbe RF, et al: Envi-
ronmental chemical exposures and disturbances of
heme synthesis. Environ Health Perspect 105:37,
1997.
71. Jensen NF, Fiddler DS, Striepe V: Anesthetic consi-
derations in porphyrias. Anesth Analg 80:591,
1995.
72. Ashley EM: Anaesthesia for porphyria. Br J Hosp
Med 56:37, 1996.
73. James MF, Hift RJ: Porphyrias. Br J Anaesth 85:143,
2000.
74. Baker SD, Taylor B: Anaesthesia is also risky in
patients with porphyria. BMJ 321:1023, 2000.
75. Marks GS, McCluskey SA, Mackie JE, et al: Disrup-
tion of hepatic heme biosynthesis after interaction
of xenobiotics with cytochrome P-450. FASEB J
2:2774, 1988.
76. Wu L,Wang R: Carbon monoxide: Endogenous pro-
duction, physiological functions, and pharmacolo-
gical applications. Pharmacol Rev 57:585, 2005.
77. Bauer M, Bauer I: Heme oxygenase-1: Redox regu-
lation and role in the hepatic response to oxidative
stress. Antioxid Redox Signal 4:749, 2002.
78. Morse D, Choi AM: Heme oxygenase-1: The “emer-
ging molecule” has arrived. Am J Respir Cell Mol
Biol 27:8, 2002.
79. Shibahara S,Kitamuro T,Takahashi K: Heme degra-
dation and human disease: Diversity is the soul of
life. Antioxid Redox Signal 4:593, 2002.
80. Moller S, Becker U: Insulin-like growth factor 1 and
growth hormone in chronic liver disease. Dig Dis
10:239, 1992.
81. Rojdmark S, Bloom G, Chou MC, et al: Hepatic
insulin and glucagon extraction after their augmen-
ted secretion in dogs. Am J Physiol 235:E88, 1978.
82. Laskin DL: Nonparenchymal cells and hepatotoxi-
city. Semin Liver Dis 10:293, 1990.
83. Dhainaut JF, Marin N, Mignon A, et al: Hepatic
response to sepsis: Interaction between coagulation
and inflammatory processes. Crit Care Med 29:S42,
2001.
84. Bosch-Morell F, Flohe L, Marin N, et al: 4-Hydroxy-
nonenal inhibits glutathione peroxidase: Protection
by glutathione. Free Radic Biol Med 26:1383, 1999.
85. Lemasters JJ: V. Necrapoptosis and the mitochon-
drial permeability transition: Shared pathways to
necrosis and apoptosis. Am J Physiol 276:G1, 1999.
86. Bautista AP, Spitzer JJ: Role of Kupffer cells in the
ethanol-induced oxidative stress in the liver. Front
Biosci 4:D589, 1999.
87. Bailey SM, Reinke LA: Antioxidants and gadoli-
nium chloride attenuate hepatic parenchymal and
endothelial cell injury induced by low flow ischemia
and reperfusion in perfused rat livers. Free Radic
Res 32:497, 2000.
88. DeLeve LD, McCuskey RS,Wang X, et al: Characte-
rization of a reproducible rat model of hepatic
veno-occlusive disease. Hepatology 29:1779, 1999.
89. Mushlin PS, Mushlin SB, Olson RD:Acute liver dys-
function and anesthesia-induced hepatitis. In
Lobato EB, Gravenstein N, Kirby RR (eds): Compli-
cations in Anesthesiology. Philadelphia, Lippincott
Wiliams & Wilkens, 2008, p 590.
90. Farrell GC: Liver disease caused by drugs, anesthe-
tics, and toxins. In Feldman M, Friedman LS, Slei-
senger MH (eds): Sleisenger & Fordtran’s
Gastrointestinal and Liver Disease: Pathophysio-
logy/Diagnosis/Management, 7th ed. St Louis, WB
Saunders, 2002, p 1403.
202 Fisiología y anestesia I